BBOT BridgeBio Oncology Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1869105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY100.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.4%
ROA-41.3%
ROIC (approx.)-116.1%
Asset turnover—
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio4.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $121.20M | $73.11M | — |
| SG&A expense | $24.62M | $7.76M | $41,692 |
| Operating income | -$145.82M | -$80.86M | -$41,692 |
| Income tax | $0 | $0 | — |
| Net income | -$134.04M | -$74.28M | -$41,692 |
| EBITDA | -$145.54M | -$80.66M | — |
| EPS (basic) | -4.30 | -5,756.41 | — |
| EPS (diluted) | -4.30 | -5,756.41 | — |
| Weighted avg. shares (diluted) | 31.14M | 12,903 | — |
| Balance sheet | |||
| Cash & equivalents | $373.69M | $30.98M | $250,000 |
| Short-term investments | $51.77M | $124.78M | — |
| Current assets | $432.40M | $158.69M | — |
| PP&E, net | $956,000 | $490,000 | — |
| Total assets | $448.38M | $164.30M | $332,894 |
| Current liabilities | $35.04M | $19.58M | $396,463 |
| Total liabilities | $37.28M | $19.58M | $396,463 |
| Shareholders' equity | $411.10M | -$178.64M | -$115.64M |
| Shares outstanding | 79.99M | 28,415 | — |
| Cash flow statement | |||
| Operating cash flow | -$113.89M | -$55.03M | — |
| Capital expenditure | $606,000 | $49,000 | — |
| Free cash flow | -$114.50M | -$55.08M | — |
| Investing cash flow | $73.33M | -$120.53M | — |
| Financing cash flow | $383.40M | $206.29M | — |
| Depreciation & amortization | $280,000 | $208,000 | — |
| Stock-based compensation | $5.87M | $4.42M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.